LifeSci Capital has begun coverage of Rapt Therapeutics (RAPT, Financial) with an Outperform rating and has set a price target of $31. This new assessment suggests a strong potential for the stock, indicating optimism in its future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for RAPT Therapeutics Inc (RAPT, Financial) is $24.75 with a high estimate of $48.00 and a low estimate of $8.00. The average target implies an upside of 111.54% from the current price of $11.70. More detailed estimate data can be found on the RAPT Therapeutics Inc (RAPT) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, RAPT Therapeutics Inc's (RAPT, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
